In summary, developing inhibitors to specifically target ARID1B nuclear translocation shows promise for a more precise therapeutic approach in breast cancer, aiming to reduce off‐target effects linked with broader chromatin remodeling inhibitors. This evidence concerns the gene ARID1B and breast cancer.